Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) EBITDA Margin (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of EBITDA Margin data on record, last reported at 357.38% in Q3 2025.

  • For Q3 2025, EBITDA Margin rose 17897.0% year-over-year to 357.38%; the TTM value through Sep 2025 reached 19.86%, up 64785.0%, while the annual FY2024 figure was 243.76%, 93560.0% up from the prior year.
  • EBITDA Margin reached 357.38% in Q3 2025 per STOK's latest filing, down from 168.51% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 71.22% in Q1 2025 and bottomed at 1226.72% in Q2 2023.
  • Average EBITDA Margin over 4 years is 589.61%, with a median of 625.0% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: tumbled -44542bps in 2023, then soared 90996bps in 2024.
  • A 4-year view of EBITDA Margin shows it stood at 768.88% in 2022, then decreased by -25bps to 957.71% in 2023, then surged by 95bps to 47.75% in 2024, then crashed by -648bps to 357.38% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 357.38% in Q3 2025, 168.51% in Q2 2025, and 71.22% in Q1 2025.